AllianceBernstein
TXG icon

AllianceBernstein’s 10x Genomics TXG Stock Holding History

AllianceBernstein’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Buy
140,581
+15,450
+12% +$405K ﹤0.01% 1823
2026
Q1 		$2.04M Sell
125,131
-1,069
-0.8% -$21.4K ﹤0.01% 1996
2025
Q4 		$2.06M Hold
126,200
– – ﹤0.01% 1987
2025
Q3 		$1.48M Sell
126,200
-307
-0.2% -$4K ﹤0.01% 2162
2025
Q2 		$1.46M Buy
126,507
+90,988
+256% +$829K ﹤0.01% 2085
2025
Q1 		$310K Buy
35,519
+24
+0.1% +$303 ﹤0.01% 2756
2024
Q4 		$510K Sell
35,495
-353
-1% -$5.57K ﹤0.01% 2634
2024
Q3 		$809K Sell
35,848
-6,670
-16% -$138K ﹤0.01% 2420
2024
Q2 		$827K Buy
42,518
+11,224
+36% +$294K ﹤0.01% 2404
2024
Q1 		$1.17M Buy
31,294
+660
+2% +$29K ﹤0.01% 2174
2023
Q4 		$1.71M Buy
30,634
+1,248
+4% +$54.3K ﹤0.01% 2022
2023
Q3 		$1.21M Sell
29,386
-888
-3% -$46.2K ﹤0.01% 2141
2023
Q2 		$1.69M Sell
30,274
-320
-1% -$17.3K ﹤0.01% 1996
2023
Q1 		$1.71M Sell
30,594
-6,325
-17% -$295K ﹤0.01% 1961
2022
Q4 		$1.35M Buy
36,919
+130
+0.4% +$4.25K ﹤0.01% 2133
2022
Q3 		$1.05M Buy
36,789
+69
+0.2% +$2.63K ﹤0.01% 2262
2022
Q2 		$1.66M Buy
36,720
+664
+2% +$34.4K ﹤0.01% 2059
2022
Q1 		$2.74M Sell
36,056
-780,682
-96% -$68.3M ﹤0.01% 1908
2021
Q4 		$122M Buy
816,738
+73,255
+10% +$11.2M 0.04% 381
2021
Q3 		$108M Buy
743,483
+89,390
+14% +$15.3M 0.04% 401
2021
Q2 		$128M Buy
654,093
+22,112
+3% +$4M 0.05% 349
2021
Q1 		$114M Sell
631,981
-150,344
-19% -$26M 0.05% 373
2020
Q4 		$111M Sell
782,325
-448,131
-36% -$65M 0.05% 347
2020
Q3 		$153M Sell
1,230,456
-301,794
-20% -$31.7M 0.08% 221
2020
Q2 		$137M Sell
1,532,250
-40,760
-3% -$3.17M 0.08% 226
2020
Q1 		$98M Buy
1,573,010
+594,693
+61% +$46.4M 0.07% 261
2019
Q4 		$74.6M Buy
978,317
+679,482
+227% +$40.9M 0.04% 418
2019
Q3 		$15.1M Buy
+298,835
New +$16.5M 0.01% 894

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AllianceBernstein's TXG Position: Q2 2026 in Review

AllianceBernstein increased its 10x Genomics (TXG) stake by 12% in Q2 2026, buying an estimated $405K and bringing the position to 140,581 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

AllianceBernstein first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $153M in Q3 2020. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • AllianceBernstein held 140,581 shares of 10x Genomics worth $2.98M as of Q2 2026.
  • AllianceBernstein bought 15,450 10x Genomics shares in Q2 2026, an estimated $405K.
  • 10x Genomics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1823 holding.
  • AllianceBernstein first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • AllianceBernstein's 10x Genomics position peaked at $153M in Q3 2020.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.